Regulated Industry Marketing: What Actually Works

Regulated industry marketing is where most agencies quietly fail. The rules are strict, the audiences are sophisticated, the legal reviews are relentless, and the launches are too expensive to get wrong. I've watched agencies treat regulated categories like any other vertical and pay for it with stalled campaigns, legal holds, and clients who don't come back. The firms that win in these spaces treat message development as a research discipline from day one, built on evidence and structured audience testing.

I'm Kurt Schmidt, and I run Schmidt Consulting Group, where I advise B2B services firms on go-to-market execution, positioning, and the kind of high-stakes launch work that regulated categories demand. Over 300-plus episodes of The Schmidt List, I've had a lot of conversations about this, and a recent one with Bob Freitag crystallized much of what I've come to believe about how regulated industry marketing actually gets done at the highest level. What follows is my synthesis of those principles.

What Makes Regulated Industry Marketing Different?

Regulated industry marketing differs from conventional marketing in one defining way: the words you choose can expose your client to legal liability, FDA enforcement action, or worse. Every claim has to be defensible. Every superlative is a potential violation.

The gap between what's approved and what actually gets advertised is wider than most marketers admit. A 2024 study in the Aesthetic Surgery Journal Open Forum, "Energy-Based Medical Devices in Plastic Surgery: A Comparison of FDA-Approved Indications to Advertised Claims," analyzed 200 websites marketing medical devices and found that 51.5% made at least one claim that deviated from FDA-approved uses. Half the market is already advertising off-label, often without realizing it. That's the risk environment you're operating in.

I learned a version of this early in my career as a designer. We used to put "free" on promotional materials without thinking twice. Turns out, in certain regulated categories, "free" carries legal precedent that "complimentary" does not. That's a small example, but it points to a larger reality: in regulated industries, the entire vocabulary is constrained. You can't say "best." You can't say "better than." You can't make comparative efficacy claims without clinical data to back them up.

So the creative challenge becomes this: how do you write something emotionally resonant, commercially effective, and legally defensible at the same time? The work is to find the truth that lives inside the constraints and make that truth do all the heavy lifting.

A few definitions worth establishing here. A strategic narrative is the overarching story a company tells the market about its product or service, encompassing positioning, emotional resonance, and proof points. A launch leadership team is a cross-functional internal group assembled specifically to align on messaging before any external work begins. An on-label claim is any product statement that has received regulatory approval and can be used legally in marketing materials. All three concepts show up constantly in effective regulated industry marketing, and I'll explain why each matters.

Why Does Internal Team Alignment Determine Launch Success Before Marketing Begins?

Internal alignment is the single biggest predictor of whether a regulated product launch gains traction or dies quietly inside the organization before it ever reaches the market. It's structural, and it comes first.

Here's what I mean. You're often marketing something that took five to seven years to develop, with hundreds of millions of dollars invested in clinical trials, FDA approvals, and product engineering. The people on that team have deep convictions about what the product is and what the market needs to hear. Those convictions frequently conflict with each other, and they almost always conflict with what the market actually responds to.

The launch leadership team concept addresses this directly. The goal is to recruit the people in the trenches: the individuals their colleagues actually go to with questions, the informal influencers inside the company. Get those people into the process early, and they become the message carriers who drive alignment across the entire organization. Skip that step, and you get what I'd call internal market gravity working against you: competing narratives, unaligned sales reps, and channel partners who don't know what to say.

I've seen launches fail before a single piece of collateral hit the market, purely because the internal team wasn't in agreement on the story. Getting everyone to a shared definition of what success looks like, including a target date and the outcomes you'll measure, is non-negotiable before any external work begins. Without it, you're building on sand.

How Do You Develop a Market-Tested Message in a Regulated Industry?

Market-tested messaging in regulated industries follows a disciplined sequence. The sequence matters more than the creativity, and skipping it is where most launches go sideways.

Start with individual discovery interviews. Group sessions produce groupthink; one-on-one conversations surface the real disagreements. When you sit people down individually and ask how they perceive the product, the initiative, and the opportunity, you get radically different answers from people on the same team. Those differences are data. They tell you where the internal narrative is fractured and where the genuine conviction lives.

From there, go external. Talk to the target audience, one person at a time, through the same deep-dive interview format. You're looking for how they describe their own problems, what language they use, what they care about emotionally, and what your client's competitors offer them that they actually value. Secondary research rounds this out: scanning how people already talk about the category, what content they engage with, what trade publications frame as the central tensions.

Then bring it all back in. Your team sits with this body of knowledge for days, working through whiteboard sessions to identify the critical insights. The best insights are almost always things the client is too close to see. After 30-plus years of doing this work, I can tell you with confidence that the message the client is most certain about is rarely the one the market responds to most strongly.

From those insights, you develop what I'd call strategic narrative territories: five to seven high-level directional options for how the product or company could be positioned. Then you filter them against three questions. Is it meaningful to the audience? Is it differentiated from competitors? Can the company actually deliver on it? You narrow to three options the whole internal team can genuinely support.

Then, and only then, do you take those three to the market for external testing. You don't assume you know what will win. You find out.

The market-testing phase consistently changes what gets built. I've seen campaigns where everyone involved was certain about the direction, and the external research came back with an entirely different winner. No product survives its first real contact with the customer, and no message does either.

Why Does Audience-First Messaging Outperform Feature-Benefit Storytelling?

In regulated industries, the instinct is always to lead with the product. You've spent years developing it, you've run clinical trials, you've got FDA approval. The data is strong, so the temptation is to lead with the data.

That instinct usually backfires, and I've seen it play out enough times to say so plainly. When the product offers only modest advantages on a feature-by-feature basis, the story becomes the differentiator.

Consider what happened with a mechanical heart valve campaign. The product itself was good, roughly on par with alternatives on a feature-by-feature basis. The real insight came from understanding the emotional landscape of cardiac surgeons at a specific moment in time: a period when interventional cardiologists were becoming the revenue drivers in hospitals, and surgeons were starting to feel overlooked. That emotional reality, feeling unseen by a market that used to center them, became the foundation of the entire campaign.

The campaign didn't open with device specs. It opened with recognition. "We see you. We understand your world." The surgeons who felt heard started preferring the product. The company went from 2% market share to 18% over a handful of years in a stagnant market. The product hadn't changed. The story had.

A different example: a perfusion product launch where the real discovery came from watching customers embrace the client's team at a trade show in Amsterdam, physically hugging them and saying "thank you for listening." The insight was that these perfusionists felt genuinely involved in developing the product. So the campaign opened with "designed by perfusionists." The audience came first. The company came second. Adoption followed.

And then there's the quiet heart valve. A campaign built around the sound, or rather the absence of it. Mechanical heart valves of a certain type make an audible clicking sound. Patients know it. Partners of patients know it. A campaign centered on the quietness of the device had nothing to do with clinical efficacy and everything to do with what patients actually cared about emotionally. A patient found that message, requested that specific product from their physician, and got the company into a hospital that had previously been inaccessible.

Buyers rationalize features and remember stories. In regulated categories where every claim has to be defensible, the emotional story is often the only territory where you have real creative freedom, and it's the territory that drives behavior.

How Do Key Opinion Leaders and Influencers Function in Regulated Industry Marketing?

Key opinion leaders, KOLs, are the trust infrastructure of regulated industries. I've worked with agencies that treated influencer strategy as something that only applied to consumer brands, and every one of them underestimated how much purchase behavior in B2B and regulated categories is driven by peer recommendation.

In medtech, pharma, and similar categories, the physician who presents at a major conference, the researcher who publishes in a respected journal, or the clinician with 30,000 engaged followers in a specialty niche carries enormous weight. It carries professional credibility, the kind that compounds over a career and outlasts any single campaign.

The goal is to arm them with the right materials, keep them on message, and amplify their reach through the channels they're already using: social media, conference presentations, journal contributions, patient community forums. You can't control what a KOL says. But you can make it easy for them to say the right things by giving them assets that make their own communication better.

Patient communities are increasingly important in this equation. Someone diagnosed with a condition will search WebMD, patient forums, and condition-specific Facebook groups before they ever talk to a physician. A campaign that shows up in those spaces with useful, accurate, emotionally resonant content can influence the conversation that happens in the exam room. I've seen that mechanism play out in pharma, and it's moving into medtech rapidly.

What Does the Sales Enablement Layer Look Like in Regulated Industry Launches?

The message doesn't end when the campaign goes live. The sales force, and often a network of independent distributors, has to carry that message into the field. If those people can't articulate the story, the launch stalls at the last mile.

In medtech especially, independent distributors are a common go-to-market channel. They carry multiple product lines, they're not employees, and they won't invest time in a product they can't sell quickly. If the messaging isn't clear and the materials aren't easy to use, they'll default to products they already understand. So the sales enablement package matters as much as the campaign. Simple, direct, on-label talking points. Clear answers to the objections they'll face. Materials that make it easy to tell the story without going off-script into legally dangerous territory.

Value analysis committees inside hospital systems add another layer. These are the bodies that evaluate new technology purchases, and they often convene only every three years. A company gets one shot to present, and frequently the person making that presentation is a physician champion inside the hospital who has to carry the argument to a committee of administrators. That champion rarely works for the company. That means the company needs to develop materials that enable someone else to tell their story effectively, someone who understands the economics of the health system, the patient outcome data, and the efficiency case. Packaging that story for a non-employee advocate is a distinct challenge, and one most marketing agencies aren't built to solve.

One honest caveat. If you're marketing an unregulated product, or you mainly need high-volume demand generation rather than this kind of multi-stakeholder narrative work, a generalist performance agency is probably a better fit than a firm built for regulated launches. The process I'm describing earns its cost when the launch is expensive, the claims are constrained, and the buying committee is complicated. Without those conditions, it becomes overhead.

Key Takeaways

• Internal team alignment is a prerequisite, and it comes before any external work. A launch leadership team built from the informal influencers people actually listen to creates the internal consensus that carries a message to market.
• Market-tested messaging beats internal conviction every time. Develop narrative territories, narrow to three the whole team can support, then validate externally before committing resources to creative development.
• Audience-first messaging outperforms feature-benefit storytelling in competitive markets. When the product offers only a modest edge, the story has to do the work.
• Regulated vocabulary constrains the words you can use. The strongest regulated industry marketing finds emotional territory that stays legally defensible and commercially powerful at the same time.
• KOL strategy is trust infrastructure. Arming key opinion leaders with the right materials amplifies reach into communities you can't access through paid media alone.
• Sales enablement and field-level materials are where campaigns live or die. The story has to survive contact with independent distributors, hospital value analysis committees, and physician champions, which is the same attraction-based positioning discipline that keeps clients coming to you.